6MW-3511

N/A

Report date: 2023/12/08 13:32:04

Base Information

Drug Name6MW-3511

Drug Alias Name6MW-3511

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionProgrammed death-ligand 1 blockersTransforming growth factor beta inhibitors

TargetsProgrammed death-ligand 1Transforming growth factor beta

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesMabwell (Shanghai) Bioscience Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMabwell (Shanghai) Bioscience Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A